ClinicalTrials.gov

History of Changes for Study: NCT05265754
The Effect of Sujok Therapy on Cancer Symptoms
Latest version (submitted February 22, 2023) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 February 22, 2022 None (earliest Version on record)
2 April 18, 2022 Study Status and Outcome Measures
3 October 9, 2022 Recruitment Status, Study Status, Study Design and Contacts/Locations
4 February 22, 2023 Study Design and Study Status
Comparison Format:

Scroll up to access the controls

Study NCT05265754
Submitted Date:  April 18, 2022 (v2)

Open or close this module Study Identification
Unique Protocol ID: Demettez
Brief Title: The Effect of Sujok Therapy on Cancer Symptoms
Official Title: The Effect of Sujok Therapy on Pain, Fatigue, Insomnia, Nausea and Vomiting Experienced by Patients With Gastrointestinal System Cancer
Secondary IDs:
Open or close this module Study Status
Record Verification: April 2022
Overall Status: Not yet recruiting
Study Start: May 1, 2022
Primary Completion: June 1, 2022 [Anticipated]
Study Completion: August 31, 2022 [Anticipated]
First Submitted: February 4, 2022
First Submitted that
Met QC Criteria:
February 22, 2022
First Posted: March 4, 2022 [Actual]
Last Update Submitted that
Met QC Criteria:
April 18, 2022
Last Update Posted: April 20, 2022 [Actual]
Open or close this module Sponsor/Collaborators
Sponsor: Ataturk University
Responsible Party: Principal Investigator
Investigator: Demet GUNES
Official Title: Principal Investigator
Affiliation: Ataturk University
Collaborators:
Open or close this module Oversight
U.S. FDA-regulated Drug: No
U.S. FDA-regulated Device: No
Data Monitoring: No
Open or close this module Study Description
Brief Summary: The aim of this study is to determine the effect of Sujok therapy on Pain, Fatigue, Insomnia, Nausea and Vomiting experienced by patients with gastrointestinal system cancer.
Detailed Description: The aim of this study is to determine the effect of Sujok treatment on Pain, Fatigue, Insomnia, Nausea and Vomiting experienced by patients with gastrointestinal system cancer. Intervention and control groups will be determined by randomization. The scales to be used in the measurement will be applied to the individuals included in the study. Then, sujok therapy will be applied to the intervention group. After 6 sessions in weeks in total, measurement tools will be applied and evaluated again.
Open or close this module Conditions
Conditions: Cancer
Keywords: Pain
Insomnia
Fatigue
Nausea and Vomiting
gastrointestinal system cancer.
sujok therapy
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Supportive Care
Study Phase: Not Applicable
Interventional Study Model: Parallel Assignment
6 sessions in 2 weeks in total of sujok therapy will be applied to the interventional group.
Number of Arms: 2
Masking: None (Open Label)
Allocation: Randomized
Enrollment: 52 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: Experimental group
In the hand area, firstly, the points will be determined by means of the diagnostic stick and massage will be applied with buckwheat seeds. This massage will be 3 sessions a week, and a total of 6 sessions in 2 weeks.
Behavioral: sujok therapy
sujok therapy
No Intervention: control group
A questionnaire will be applied to the patients by the researcher. Questionnaires will be made as pre-test and post-test.
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Sujok Therapy's Positive Change in Pain Experienced by Gastrointestinal System Cancer Patients
[ Time Frame: 2 weeks ]

To assess the pain, the MCgill Pain Scale will be applied before starting the sujok application and after the sujok applied for 2 weeks.
2. Sujok Therapy's positive change in Fatigue Experienced by Patients with Gastrointestinal System Cancer
[ Time Frame: 2 weeks ]

To assess the fatigue, the cancer fatigue scale will be applied before starting the sujok application and after the sujok applied for 2 weeks.
3. Sujok Therapy's positive cahange in insomnia Experienced by Patients with Gastrointestinal System Cancer
[ Time Frame: 2 weeks ]

In order to evaluate insomnia,the insomnia severity index will be applied before starting the sujok application and after the sujok applied for 2 weeks
4. Sujok Therapy's positive cahange in nausea and vomiting Experienced by Patients with Gastrointestinal System Cancer
[ Time Frame: 2 weeks ]

To evaluate nausea and vomiting, the Rhodes nausea vomiting scale will be applied before starting the sujok application and after the sujok applied for 2 weeks
Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age:
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

Inclusion Criteria:

  • over 18 years old
  • Fatigue Severity Measurement - Visual Analogue Scale (VAS) fatigue score of 3 and above,
  • Pain Severity Measurement - Visual Analogue Scale (VAS) pain score of 3 and above,
  • Measurement of Nausea and Vomiting Severity - Patients with a Visual Analogue Scale (VAS) nausea and vomiting score of 3 and above will be included.

Exclusion Criteria:

  • Loss of sensation, amputation, injury, colostomy, etc., which will prevent practice in hands. patients will be excluded from the study.
Open or close this module Contacts/Locations
Locations:
Open or close this module IPDSharing
Plan to Share IPD: No
Open or close this module References
Citations:
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services